// App-Quantinova.ai

11560 : The landscape of clinically actionable ALK/MET/RET/ROS1 fusions to reveal a shared pattern of protein domains in fusion partners.

Researchers

Presenter

  • Lauren Ritterhouse

Principal Investigators

  • Dora Dias-Santagata

  • Valentina Nardi

  • A. John Iafrate

  • Long P. Le

  • Jochen K Lennerz

Medical Centers

  • Massachusetts General Hosp Harvard Medcl School, Boston, MA

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Solid malignancies

Biomarkers

  • Anaplastic lymphoma Kinase

  • Proto-oncogene tyrosine-protein kinase ROS

  • Ret Proto-Oncogene

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved